Biolevate, an AI-native knowledge platform company for life sciences, today announced it is building with the NVIDIA BioNeMo Agent Toolkit to support the next phase of its agentic discovery roadmap.

The company’s AQCat model for materials and catalyst discovery will be available first, followed by AQPotency for drug ...

AI drug discovery cleared its first Phase IIa clinical test in 2025, as BIO 2026 confirmed the shift from speculation to ...

Discover how AI, automation, and next-generation DMTA workflows are accelerating drug discovery with expert insights from TTP ...

Drug discovery is notoriously inefficient. Pharmaceutical projects span years, moving from one specialized human team to the ...

Developing new medicines can require thousands of chemistry experiments to identify the right recipe for a safe, effective ...

Discover why animal models fall short in AI drug discovery and how human-first datasets and functional genomics are changing ...

Insilico Medicine ("Insilico", 3696.HK ), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in ...

Artificial intelligence has already made its mark in commercial industries, and there's a good argument to be made that AI is ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Modern Medical Research Laboratory. Scientific Lab, Drug Engineering Center Full of ...

Executives from Lila Sciences and NVIDIA told Fortune that the convergence of AI and biology could redefine global competitiveness for decades.